As of 2025-07-13, the EV/EBITDA ratio of Spero Therapeutics Inc (SPRO) is -1.48. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SPRO's latest enterprise value is 108.22 mil USD. SPRO's TTM EBITDA according to its financial statements is -72.98 mil USD. Dividing these 2 quantities gives us the above SPRO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.1x - 13.3x | 10.7x |
| Forward P/E multiples | 12.3x - 20.5x | 16.4x |
| Fair Price | (15.18) - (16.49) | (16.81) |
| Upside | -640.3% - -686.7% | -698.3% |
| Date | EV/EBITDA |
| 2025-07-11 | -1.48 |
| 2025-07-10 | -1.51 |
| 2025-07-09 | -1.66 |
| 2025-07-08 | -1.58 |
| 2025-07-07 | -1.55 |
| 2025-07-03 | -1.56 |
| 2025-07-02 | -1.55 |
| 2025-07-01 | -1.55 |
| 2025-06-30 | -1.55 |
| 2025-06-27 | -1.58 |
| 2025-06-26 | -1.55 |
| 2025-06-25 | -1.55 |
| 2025-06-24 | -1.54 |
| 2025-06-23 | -1.57 |
| 2025-06-20 | -1.64 |
| 2025-06-18 | -1.58 |
| 2025-06-17 | -1.55 |
| 2025-06-16 | -1.51 |
| 2025-06-13 | -1.50 |
| 2025-06-12 | -1.54 |
| 2025-06-11 | -1.48 |
| 2025-06-10 | -1.51 |
| 2025-06-09 | -1.44 |
| 2025-06-06 | -1.25 |
| 2025-06-05 | -1.29 |
| 2025-06-04 | -1.37 |
| 2025-06-03 | -1.35 |
| 2025-06-02 | -1.43 |
| 2025-05-30 | -1.25 |
| 2025-05-29 | -0.96 |
| 2025-05-28 | -1.13 |
| 2025-05-27 | 0.15 |
| 2025-05-23 | 0.14 |
| 2025-05-22 | 0.14 |
| 2025-05-21 | 0.14 |
| 2025-05-20 | 0.15 |
| 2025-05-19 | 0.14 |
| 2025-05-16 | 0.17 |
| 2025-05-15 | 0.17 |
| 2025-05-14 | 0.17 |
| 2025-05-13 | 0.14 |
| 2025-05-12 | 0.20 |
| 2025-05-09 | 0.19 |
| 2025-05-08 | 0.23 |
| 2025-05-07 | 0.23 |
| 2025-05-06 | 0.22 |
| 2025-05-05 | 0.20 |
| 2025-05-02 | 0.17 |
| 2025-05-01 | 0.16 |
| 2025-04-30 | 0.17 |